| Name | FPS-ZM1 |
| Description | FPS-ZM1 is a high-affinity, RAGE-specific inhibitor that obstructs Aβ binding to the V domain of RAGE. |
| Cell Research | CHO cells are treated for 72 hours with different concentrations of inhibitors ranging from 10 nM to 10 μM. The cellular toxicity was determined using the WST-8 Assay Kit. (Only for Reference) |
| Kinase Assay | Human sRAGE is immobilized (10 μg/mL) overnight at 4°C in 96-well microtiter plates and blocked with 3% bovine serum albumin. 125I-labeled Aβ40, HMGB1, or S100B at 5 nM in the absence and presence of various concentrations of FPS2 or FPS-ZM1 (10 to 1,000 nM) is added to the wells containing immobilized sRAGE and incubated for 1 hour at room temperature in PBS. Wells are washed with cold PBS to remove unbound radiolabeled ligands, and the radioactivity is analyzed[1]. |
| In vitro | FPS-ZM1 blocks Aβ binding to the V domain of RAGE and inhibited Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro. It blocks binding of other ligands to RAGE as well, such as S100B, AGE, and HMGB1, which have been suggested to contribute to RAGE-mediated long-term tissue damage in models of diabetes, immune/inflammatory disorders, and AD[1]. |
| In vivo | FPS-ZM1 is nontoxic to mice and readily crossed the blood-brain barrier (BBB).It effectively controls progression of an Aβ-mediated brain disorder and the related neurovascular and cognitive dysfunction in 17-month-old APPsw/0 mice with fully developed Aβ and amyloid pathology by blocking RAGE actions at the BBB and in brain. Also, FPS-ZM1 blocks RAGE-dependent BACE1 expression and activity in brain of 17-month-old APPsw/0 mice[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.1 mM), Sonication is recommended.
DMSO : 257.5 mg/mL (785.42 mM), Sonication is recommended.
|
| Keywords | β-amyloid peptide | βAmyloid | β Amyloid | RAGE | Inhibitor | inhibit | FPS-ZM-1 | FPS-ZM1 | FPSZM1 | FPS ZM1 | BetaAmyloid | Beta Amyloid | bAmyloid | b Amyloid | Amyloid-β | advancedglycationendproducts | advanced glycation end products | Abeta |
| Inhibitors Related | Benzenesulfonamide | Deferoxamine Mesylate | Ipriflavone | HEPPS | Phytic acid sodium salt | Rutin | Resveratrol | 10-Undecenoic acid | 2,4-Di-tert-butylphenol | Chlorzoxazone | Methyl tridecanoate | Glimepiride |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Multi-Target Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max |
United States
